RJA
CBPO

Raymond James & Associates’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Raymond James & Associates’s Portfolio CBPO Stock Details CBPO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-2,818
Closed -$303K – 3466
2016
Q4 		$303K Buy
2,818
+582
+26% +$68K ﹤0.01% 2618
2016
Q3 		$278K Buy
+2,236
New +$264K ﹤0.01% 2670

Other funds holding CBPO

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
HIM
Hermes Investment Management London Uk, United Kingdom $7.52B AUM 20.67% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Raymond James & Associates's CBPO Position: Q1 2017 in Review

Raymond James & Associates sold out of China Biologic Products Holdings, Inc. (CBPO) in Q1 2017, closing a stake of 2,818 shares — an estimated $303K sold.

Raymond James & Associates first reported a position in CBPO in Q3 2016 and held it in 2 quarters. The position peaked at $303K in Q4 2016. 137 funds tracked by Wall St. Rank hold CBPO as of Q1 2017.

  • Raymond James & Associates reported no remaining China Biologic Products Holdings, Inc. position as of Q1 2017 after selling out during the quarter.
  • Raymond James & Associates sold 2,818 China Biologic Products Holdings, Inc. shares in Q1 2017, an estimated $303K.
  • Raymond James & Associates first reported a position in China Biologic Products Holdings, Inc. in Q3 2016 and held it in 2 quarters.
  • Raymond James & Associates's China Biologic Products Holdings, Inc. position peaked at $303K in Q4 2016.
  • 137 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q1 2017.

Based on Raymond James & Associates's 13F filing for Q1 2017, filed 15 May 2017.